November 15, 2019 PR/Corporate

QIAGEN receives several conditional, non-binding indications of interest, enters into discussions to explore potential strategic alternatives

Venlo, The Netherlands, November 15, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management... Read more

November 6, 2019 Life Science Tools Product Launch

QIAGEN launches novel NGS workflow for simultaneous DNA and RNA analysis for use in cancer profiling at 2019 AMP Annual Meeting

QIAseq® Multimodal Panels streamline simultaneous DNA and RNA sequencing for comprehensive solid and liquid tumor profiling Only solution to extract, enrich and sequence DNA variants and RNA fusions and assess gene expression in a single workflow from a single sample within a single day QIAGEN to highlight extensive Sample to Insight portfolio for clinical laboratories... Read more

November 5, 2019 Clinical Research/Diagn. PAI Top-10

QIAGEN expands portfolio of immuno-oncology assets for future companion diagnostics and biomarkers

Collaborates with Repertoire Genesis for access to T-cell /B-cell receptor repertoire assays for clinical next-generation sequencing Acquires licensing rights for epigenomic (DNA methylation) immune checkpoint inhibitor biomarkers developed by researchers from the University of Bonn Receives exclusive license to novel mRNA gene expression signatures from STRATIFYER Molecular Pathology GmbH which may guide treatment decisions for... Read more

October 14, 2019 Life Science Tools Product Launch

QIAGEN launches new QIAseq FastSelect solutions to accelerate RNAseq

Hilden, Germany, and Germantown, Maryland, October 14, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of innovative new technologies for faster, simpler library preparation for next-generation sequencing (NGS) in the growing field of RNA research. QIAGEN is showcasing its industry-leading portfolio of universal NGS solutions at ASHG 2019, the annual... Read more

October 7, 2019 Clinical Research/Diagn. Environ, Ag./Food & Bev Life Science Tools M&A, Partnerships

QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

San Diego, California, Hilden, Germany and Germantown, Maryland – October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. The agreement grants QIAGEN non-exclusive... Read more

October 7, 2019 Licensing, IP, and Legal

QIAGEN announces CEO leadership transition

Peer M. Schatz to step down as CEO to pursue new opportunities Remains as Special Advisor to facilitate a smooth transition Search started for permanent CEO to lead QIAGEN in next growth phase Thierry Bernard to act as interim CEO, working in tandem with CFO Roland Sackers Venlo, The Netherlands, October 7, 2019 – QIAGEN... Read more

October 7, 2019 Uncategorized

QIAGEN reports preliminary Q3 2019 results and announces measures to prioritize resource allocation

Preliminary Q3 2019 sales of about 3% CER growth (vs.~4-5% CER outlook), adjusted EPS in line with outlook Initiatives announced to free up resources to invest in best growth opportunities, in particular new partnership with Illumina in NGS clinical decision-making Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today... Read more

September 30, 2019 Life Science Tools M&A, Partnerships Product Launch

QIAGEN launches enhanced GeneGlobe Design & Analysis Hub, combining curated knowledge, content-based assays and analyses for life science research

Hilden, Germany, and Germantown, Maryland, September 30, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its newly enhanced GeneGlobe Design & Analysis Hub, bringing next-level experiment planning, execution and follow-up to life science researchers. GeneGlobe integrates QIAGEN’s deep, manually curated knowledge base on over 10,000 biological entities with the... Read more

September 16, 2019 PR/Corporate

QIAGEN announces winners of 2019 Young Investigator Award competition

Germantown, Maryland, and Hilden, Germany, September 16, 2019 – QIAGEN today announced the winners of its first Young Investigator Award competition for outstanding researchers in forensic science. The 2019 award winner and two runners-up were recognized during the International Society for Forensic Genetics (ISFG) Congress in Prague. The 2019 Young Investigator Award was awarded to... Read more